Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone

Hypertension

Volumn 41, Issue 3 I, 2003, Pages 598-603

  Fukuyama, Kae ^a   Ichiki, Toshihiro ^a   Takeda, Kotaro ^a   Tokunou, Tomotake ^a   Iino, Naoko ^a   Masuda, Satoko ^a   Ishibashi, Minako ^a   Egashira, Kensuke ^a   Shimokawa, Hiroaki ^a   Hirano, Katsuya ^a   Kanaide, Hideo ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Gene expression; Hormones; mRNA stability; Receptors, angiotensin II; Vascular relaxation

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; IODINE 125; LIOTHYRONINE; LUCIFERASE; MESSENGER RNA; THYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE ACTIVITY; GENE EXPRESSION; HORMONAL REGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; AORTA; BLOOD VESSELS; CALCIUM; CELLS, CULTURED; DOWN-REGULATION; GENE EXPRESSION REGULATION; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; REPRESSOR PROTEINS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRIIODOTHYRONINE, REVERSE;

EID: 0037338269     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000056524.35294.80     Document Type: Article

References (29)

1. Brent GA. The molecular basis of thyroid hormone action. N Engl J Med. 1994;331:847-853.
2. Zhang J, Lazar MA. The mechanism of action of thyroid hormones. Annu Rev Physiol. 2000;62:439-466.
3. Morkin E. Regulation of myosin heavy chain genes in the heart. Circulation. 1993;87:1451-1460.
4. Ojamaa K, Klemperer JD, MacGilvray SS, Klein I, Samarel A. Thyroid hormone and hemodynamic regulation of β-myosin heavy chain promoter in the heart. Endocrinology. 1996; 137:802-808.
5. 2+ transport and myocardial relaxation. Circ Res. 1994;75:245-251.
6. Klein I, Ojamaa K. Thyroid hormone: targeting the vascular smooth muscle cell. Circ Res. 2001;88:260-261.
7. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-509.
8. Mizuma H, Murakami M, Mori M. Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res. 2001;88:313-318.
9. Ojamaa K, Klemperer JD, Klein I. Acute effects of thyroid hormone on vascular smooth muscle. Thyroid. 1996;6:505-512.
10. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature. 1991;351:230-233.
11. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993;268:24543-24546.
12. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639-672.
13. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA. 2000; 97:931-936.
14. Funakoshi Y, Ichiki T, Ito K, Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension. 1999;34:118-125.
15. Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshita A. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension. 1998;31:342-348.
16. Tokunou T, Ichiki T, Takeda K, Funakoshi Y, Iino N, Shimokawa H, Egashira K, Takeshita A. Thrombin induces interleukin-6 expression through the cAMP response element in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:1759-1763.
17. Takeda K, Ichiki T, Funakoshi Y, Ito K, Takeshita A. Downregulation of angiotensin II type 1 receptor by all-trans retinoic acid in vascular smooth muscle cells. Hypertension. 2000;35:297-302.
18. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, lino N, Hirano K, Kanaide H, Takeshita A. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-1839.
19. Kakizawa T, Miyamoto T, Ichikawa K, Takeda T, Suzuki S, Mori J, Kumagai M, Yamashita K, Hashizume K. Silencing mediator for retinoid and thyroid hormone receptors interacts with octamer transcription factor-1 and acts as a transcriptional repressor. J Biol Chem. 2001;276: 9720-9725.
20. Lee SK, Kim JH, Lee YC, Cheong J, Lee JW. Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-κB, and serum response factor. J Biol Chem. 2000;275:12470-12474.
21. Sernia C, Marchant C, Brown L, Hoey A. Cardiac angiotensin receptors in experimental hyperthyroidism in dogs. Cardiovasc Res, 1993;27: 423-428.
22. Marchant C, Brown L, Sernia C. Renin-angiotensin system in thyroid dysfunction in rats. J Cardiovasc Pharmacol. 1993;22:449-455.
23. Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation. 1993;87:1435-1441.
24. Napoli R, Biondi B, Guardasole V, Matarazzo M, Pardo F, Angelini V, Fazio S, Sacca L. Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation. 2001;104:3076-3080.
25. Barth JD, Jansen H, Kromhout D, Reiber JH, Birkenhager JC, Arntzenius AC. Progression and regression of human coronary atherosclerosis: role of lipoproteins, lipases and thyroid hormones in coronary lesion growth. Atherosclerosis. 1987;68:51-58.
26. Lev-Ran A. Thyroid hormones and prevention of atherosclerotic heart disease: an old-new hypothesis. Perspect Biol Med. 1994;37:486-494.
27. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
28. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586-1593.
29. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.